PT - JOURNAL ARTICLE AU - Marcus Inyama Asuquo AU - Emmanuel Effa AU - Akaninyene Otu AU - Okokon Ita AU - Ubong Udoh AU - Victor Umoh AU - Oluwabukola Gbotosho AU - Anthonia Ikpeme AU - Soter Ameh AU - William Egbe AU - Margaret Etok AU - Jochen Guck AU - Andrew Ekpenyong TI - Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients AID - 10.1101/2020.07.02.20145441 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.02.20145441 4099 - http://medrxiv.org/content/early/2020/07/24/2020.07.02.20145441.short 4100 - http://medrxiv.org/content/early/2020/07/24/2020.07.02.20145441.full AB - The coronavirus disease 2019 (COVID-19) is now a pandemic with devastating social and economic consequences. The extent of the spread of COVID-19 within populations is uncertain since diagnostic tests have not been carried out on all eligible persons and doing such diagnostic tests on everyone is much less feasible in developing countries such as Nigeria. Tests for antibodies to SARS-CoV-2, the virus that causes COVID-19, are more affordable, readily available, and require minimal training than current diagnostic tests. Employing a seroepidemiological strategy, serological tests were conducted on 66 volunteering staff and patients at the University of Calabar Teaching Hospital (UCTH), a Federal Government owned tertiary healthcare facility, to determine the extent of exposure to SARS-CoV-2, from 17th to 25th June 2020. Using a COVID-19 IgG/IgM Rapid Test Cassette with emergency use authorization (EUA) from the Food and Drug Administration (FDA) of the United States, it was observed that of the 66 samples tested, 5 (7.6%) were both IgG and IgM positive and 17 (26%) were IgG positive. Moreover, for 44 of the 66 participants, simultaneous tests were carried out using a rapid test kit from a different manufacturer but without FDA-EUA and all the results completely matched with the FDA-EUA kit, except one case where the FDA-EUA kit showed positive for both IgG and IgM while the other kit was positive only for IgM. The 26% positive IgG indicates a high exposure rate for the hospital staff and patients and points to community transmission where the facility is situated. Hence, immediate activation of WHO guidelines for controlling community transmission is called for. These results can further serve as a pilot study to guide public health policies in response to COVID-19 pandemic in both the general population and in healthcare settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no external funding for this work. However, the Joseph Ukpo Hospitals and Research Institutes, JUHRI, provided partial funding from donations made through Friends of JUHRI, a 501(c)3 non-profit organization and public charity. JUHRI provides 100% free healthcare to the rural poor in Akwa Ibom and Cross River States of Nigeria.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received ethical approval (UCTH/HREC/33/703) from the University of Calabar Teaching Hospital Health Research Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the paper is available upon request.